ClinicalTrials.gg
RecruitingNCT05260307Updated Sep 28, 2026

Improving Spatial Perception and Speech Understanding in Multitalker Mixtures

An interventional study of hearing aid condition in Hearing Loss, sponsored by Boston University Charles River Campus. Recruiting at 1 site in United States. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-28.

Sponsored by Boston University Charles River Campus · Not applicable, Interventional, and Basic science

How we know

From the registry’s dates

  • Started Mar 2022; still recruiting 4 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
220
Allocation
Not applicable
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 321 studies in Hearing Loss with a site in United States — 82 open to participants now, 94 under way, 3 of them phase 3. Hearing Loss · United States.

Planned enrollment
43rd of 272
220 · median 48
Started
2022
with 22 others
No phase
212 of 321
54 open now
Primary completion
2026-11
later than 18 of 93 live
Registered
205th of 321
by date

Among the 321 studies in Hearing Loss with a site in United States, this one is the 43rd largest by planned enrollment of the 272 interventional ones that give a count, is one of 23 that started in 2022, is one of 212 with no phase, reaches primary completion later than 18 of the 93 other live ones, and was the 205th registered.

Hearing Loss

797 studies on the registry are indexed under Hearing Loss; 194 are open to participants now.

Browse Hearing Loss studies →

Open to participants now

82 of the 321 studies in Hearing Loss with a site in United States are open now. Recruiting first, the newest first:

77 more — sign in →

All 82 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 125 Hearing Loss studies recruiting now, 60 (48%) set no upper age limit and 43 (34%) stop at 75 or younger; 47 take children under 18; 46 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 321 studies in Hearing Loss with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to investigate several approaches for improving spatial perception and speech intelligibility in multitalker listening situations for hearing-aid users. The hypotheses are that spatial perception and speech intelligibility will be improved by (1) increased high-frequency audibility, (2) speech envelope enhancement, and/or (3) appropriate sound image externalization.

Read the detailed description

The purpose of this study is to investigate several approaches for improving spatial perception and speech intelligibility in multitalker listening situations for hearing-aid users. Aim 1 will investigate how well different amplification strategies provide access to the spectrotemporally sparse speech information that is available in multitalker mixtures. The hypothesis is that subtle differences in high-frequency audibility across different strategies may have much greater effects on the intelligibility of sparse speech than intact speech. This Aim will involve 40 subjects with hearing loss across 2 experiments. Aim 2 is an exploratory aim that will investigate the potential of a speech enhancement algorithm to improve spatial hearing in multitalker mixtures. The hypothesis is that speech enhancement, in addition to its established monaural benefits, will enhance the salience of interaural time differences and thus provide binaural benefits in multitalker mixtures. This Aim will involve 30 subjects with normal hearing and 60 subjects with hearing loss across 3 experiments. Aim 3 will investigate how different hearing-aid styles affect sound externalization. The hypothesis is that hearing aids can disrupt sound externalization, which in turn impacts speech intelligibility in multitalker mixtures. This Aim will involve 30 subjects with normal hearing and 60 subjects with hearing loss across 3 experiments.

This is a prospective design involving adult human subjects. While the investigators will recruit subjects with normal and impaired hearing, all subjects will be assigned to the same set of experimental conditions. Therefore, for the purposes of intervention (or prospective assignment), the subjects can be treated as a single group completing the same intervention (or set of interventions). The behavioral experiments involve listening to speech sounds (either unaided, with hearing aids, or with simulated hearing aids), and providing responses related to spatial perception or speech intelligibility. The order of experimental conditions will be randomized for each subject in order to control for order effects. All of the experimental tasks and outcome measures have been previously established, have good reliability and validity, and will be appropriate for informing future studies.

03

Conditions studied

  • Hearing Loss

Keywords

  • Hearing Aids
  • Speech Intelligibility
  • Spatial Hearing
  • Cocktail Party
  • Audibility
  • Sound Image Externalization
  • Speech Envelope
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria: Normal-Hearing Subjects

  • 18 to 35 years of age
  • Audiometric thresholds that do not exceed 20 dB HL at any frequency from 250 to 8000 Hz
  • Able to provide and understand experimental instructions
  • Normal or corrected-to-normal vision

Inclusion Criteria: Hearing-Impaired Subjects

  • 18 to 80 years of age
  • Documented sensorineural hearing loss
  • Able to provide informed consent and understand experimental instructions
  • Normal or corrected-to-normal vision

Exclusion Criteria (some experiments)

  • Non-native speakers of English
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
220 participants (estimated)

Study arms

  • Other
    Experimental condition

    Participants will be presented with sound stimuli under a number of experimental conditions that simulate different hearing-aid conditions.

    Other: hearing aid condition

Interventions

  • Otherhearing aid condition

    The intervention will be a hearing aid or a modification to the sound stimulus that simulates a hearing aid configuration, style, or processing strategy.

06

What researchers measure

Primary outcomes

  1. Speech intelligibility at baseline

    Speech intelligibility scores will be measured in a baseline condition (e.g. unaided) and in a number of hearing-aid conditions (post-intervention). Scale is in percent correct (0-100%).

    Time frame: Baseline

  2. Speech intelligibility post-intervention

    Speech intelligibility scores will be measured in a baseline condition (e.g. unaided) and in a number of hearing-aid conditions (post-intervention). Scale is in percent correct (0-100%).

    Time frame: Up to 4 hours

  3. Speech reception threshold at baseline

    Speech reception thresholds will be measured in a baseline condition (e.g. unaided) and in a number of hearing-aid conditions (post-intervention). Scale is in decibels (the level of the target speech relative to the masker speech needed to identify 50% of the words in a sentence).

    Time frame: Baseline

  4. Speech reception threshold post-intervention

    Speech reception thresholds will be measured in a baseline condition (e.g. unaided) and in a number of hearing-aid conditions (post-intervention). Scale is in decibels (the level of the target speech relative to the masker speech needed to identify 50% of the words in a sentence).

    Time frame: Up to 4 hours

  5. Interaural time difference discrimination at baseline

    Thresholds for the discrimination of interaural time differences in speech will be measured in a baseline condition (e.g. unaided) and in a number of hearing-aid conditions (post-intervention). Scale is in microseconds.

    Time frame: Baseline

  6. Interaural time difference discrimination post-intervention

    Thresholds for the discrimination of interaural time differences in speech will be measured in a baseline condition (e.g. unaided) and in a number of hearing-aid conditions (post-intervention). Scale is in microseconds.

    Time frame: Up to 4 hours

  7. Externalization rating at baseline

    Externalization judgments for speech will be measured in a baseline condition (e.g. unaided) and in a number of different hearing-aid conditions (post-intervention). Scale is in percent (0-100%).

    Time frame: Baseline

  8. Externalization rating post-intervention

    Externalization judgments for speech will be measured in a baseline condition (e.g. unaided) and in a number of different hearing-aid conditions (post-intervention). Scale is in percent (0-100%).

    Time frame: Up to 4 hours

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Individual participant data that underlie results in a publication will be made publicly available.

Time frame: The data will be made available at the time of the relevant publication.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2022 (actual). Primary completion is estimated for Nov 2026, 56 months after the start.

Of 197 non-industry interventional studies with no phase under Hearing Loss, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 59. This study's planned 56 months is above that.

Counting every sponsor, half of 323 studies reached it within 19 months; a quarter within 5 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 4, 2022
First posted
Mar 2, 2022
StartActual
Mar 9, 2022
Primary completionEst.
Nov 30, 2026
CompletionEst.
Nov 30, 2026
Last update
Sep 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
1 update, last Sep 28, 2026
Show all 1 update
  1. Sep 28, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05260307
Responsible party
Sponsor
First posted
Mar 2, 2022
Start date
Mar 9, 2022
Primary completion
Nov 30, 2026 (estimated)
Completion
Nov 30, 2026 (estimated)
Last update
Sep 28, 2026

Study contacts

Virginia A Best, PhD
Contact
ginbest@bu.edu
(617) 353-2622
Christine Mason
Contact
cmason@bu.edu
cmason@bu.edu
Virginia A Best, PhD
principal investigator · Boston University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion